SCHEMBL3347874

SCHEMBL3347874

BrCCn1ccc2ccccc21

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 4/20 0.76
CCND1 P24385 4/20 0.76
HTR2A P28223 1/20 0.59
HTR2C P28335 1/20 0.59
LMNA P02545 1/20 0.56
KMT2A Q03164 1/20 0.52
MAPK1 P28482 2/20 0.51
HTT P42858 1/20 0.51
ALDH1A1 P00352 1/20 0.49
HTR6 P50406 1/20 0.49
DAO P14920 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47
MTNR1A P48039 1/20 0.46
MTNR1B P49286 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30631687 1.00 CDK4 (0.76) CDK4CCND1HTR2AHTR2CLMNA
SCHEMBL2357919 0.88 CDK4 (0.78) CDK4CCND1HTR2AHTR2CLMNA
SCHEMBL11366447 0.87 CDK4 (1.00) CDK4CCND1HTR2AHTR2CLMNA
SCHEMBL29571527 0.86 CDK4 (0.81) CDK4CCND1HTR2AHTR2CLMNA
SCHEMBL2410943 0.86 CDK4 (0.81) CDK4CCND1HTR2AHTR2CLMNA
SCHEMBL9702210 0.85 CDK4 (0.82) CDK4CCND1HTR2AHTR2CLMNA
SCHEMBL6396944 0.85 CDK4 (0.82) CDK4CCND1HTR2AHTR2CLMNA
SCHEMBL3887125 0.83 CDK4 (0.68) CDK4CCND1HTR2AHTR2CLMNA
SCHEMBL3330892 0.79 CDK4 (0.76) CDK4CCND1HTR2AHTR2CLMNA
SCHEMBL734246 0.79 CDK4 (0.76) CDK4CCND1HTR2AHTR2CLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117024759-A Organic Pt metal macrocyclic group two-dimensional supermolecule assembly constructed based on oriented cation-pi action, and preparation method and application thereof 陕西中医药大学 2023-11-10 CN disclosed
WO-2010059711-A1 SIGMA-1 RECEPTOR LIGANDS AND METHODS OF USE WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2010-05-27 WO disclosed
US-6992085-B2 Octahydro-2H-pyrido[1,2-a]pyrazine compounds LES LABORATORIES SERVIER (FR) 2006-01-31 US disclosed
EP-1275647-B1 Octahydro-2H-pyrido[1,2-a]pyrazine derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2003-11-12 EP disclosed
US-20030195216-A1 Octahydro-2H-pyrido[1,2-a] pyrazine compounds LES LABORATOIRES SERVIER (FR) 2003-10-16 US disclosed
EP-1275647-A1 Octahydro-2H-pyrido[1,2-a]pyrazine derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2003-01-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195216-A1 Octahydro-2H-pyrido[1,2-a] pyrazine compounds CYP2W1, OXER1, IL1R1 CDK4 3161/4885CCND1 674/4885HTR2A 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.